{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:21:24Z","timestamp":1792801284827,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","award":["KotK_UG\/2020\/12184\/1"],"award-info":[{"award-number":["KotK_UG\/2020\/12184\/1"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jchromb.2023.123980","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T11:49:19Z","timestamp":1704541759000},"page":"123980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Development and validation of an UPLC-MS\/MS method for the determination of irinotecan (CPT-11), SN-38 and SN-38 glucuronide in human plasma and peritoneal tumor tissue from patients with peritoneal carcinomatosis"],"prefix":"10.1016","volume":"1233","author":[{"given":"Elke","family":"Gasthuys","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"van Ovost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Vande Casteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cosyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Ceelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Van Bocxlaer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2023.123980_b0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jpba.2012.04.003","article-title":"A new UPLC-MS\/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics","volume":"66","author":"Goldwirt","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123980_b0010","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00228-010-0885-3","article-title":"Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration","volume":"66","author":"Ahn","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jchromb.2023.123980_b0015","first-page":"641","article-title":"Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins","volume":"8","author":"Garcia-Carbonero","year":"2002","journal-title":"Clin. Can. Res. off. J. Am. Assoc. Can. Res."},{"key":"10.1016\/j.jchromb.2023.123980_b0020","first-page":"2182","article-title":"Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)","volume":"7","author":"Mathijssen","year":"2001","journal-title":"Clin. Can. Res. Off. J. Am. Assoc. Can. Res."},{"key":"10.1016\/j.jchromb.2023.123980_b0025","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jchromb.2023.123980_b0030","doi-asserted-by":"crossref","first-page":"e0118194","DOI":"10.1371\/journal.pone.0118194","article-title":"Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic study","volume":"10","author":"Marangon","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jchromb.2023.123980_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.710945","article-title":"Microbiota-host-irinotecan axis: A New insight toward irinotecan chemotherapy","volume":"11","author":"Yue","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.jchromb.2023.123980_b0040","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22217","article-title":"Determination of irinotecan, SN-38 and SN-38 glucuronide using HPLC\/MS\/MS: Application in a clinical pharmacokinetic and personalized medicine in colorectal cancer patients","volume":"32","author":"Atasilp","year":"2018","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.jchromb.2023.123980_b0045","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jpba.2017.11.079","article-title":"Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection","volume":"150","author":"Hahn","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123980_b0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpba.2019.03.034","article-title":"A validated UPLC-MS\/MS method to determine free and total irinotecan and its two metabolites in human plasma after intravenous administration of irinotecan hydrochloride liposome injection","volume":"170","author":"Zhuang","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jchromb.2023.123980_b0055","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jchromb.2016.02.012","article-title":"Development and validation of an UPLC-MS\/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats","volume":"1015\u20131016","author":"Basu","year":"2016","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2023.123980_b0060","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/sj.bjc.6604673","article-title":"Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients","volume":"99","author":"Rouits","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jchromb.2023.123980_b0065","unstructured":"EMA. Guideline on bioanalytical method validation. EMEACHMPEWP1922172009 Rev 1 Corr 2 2011."},{"key":"10.1016\/j.jchromb.2023.123980_b0070","unstructured":"FDA. Bioanalytical Method Validation Guidance for Industry 2018."},{"key":"10.1016\/j.jchromb.2023.123980_b0075","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.talanta.2014.05.028","article-title":"Enzymatic tumour tissue digestion coupled to SPE-UPLC-Tandem Mass Spectrometry as a tool to explore paclitaxel tumour penetration","volume":"129","author":"Colin","year":"2014","journal-title":"Talanta"},{"key":"10.1016\/j.jchromb.2023.123980_b0080","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1158\/0008-5472.CAN-14-0572","article-title":"Preclinical activity of nanoliposomal irinotecan is governed by tumor deposition and intratumor prodrug conversion","volume":"74","author":"Kalra","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.jchromb.2023.123980_b0085","first-page":"2605","article-title":"Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan1","volume":"8","author":"Xu","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jchromb.2023.123980_b0090","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1016\/j.jchromb.2009.07.025","article-title":"Quantitation of Irinotecan and its two major metabolites using a liquid chromatography-electrospray ionization tandem mass spectrometric","volume":"877","author":"Zhang","year":"2009","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jchromb.2023.123980_b0095","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","article-title":"Individualization of Irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics","volume":"57","author":"de Man","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jchromb.2023.123980_b0100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/(SICI)1097-0215(19991112)83:4<491::AID-IJC10>3.0.CO;2-M","article-title":"pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells","volume":"83","author":"Kobayashi","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jchromb.2023.123980_b0105","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1006\/abio.2001.5317","article-title":"High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells","volume":"297","author":"Boyd","year":"2001","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jchromb.2023.123980_b0110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/jps.2600810718","article-title":"A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues","volume":"81","author":"Fassberg","year":"1992","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jchromb.2023.123980_b0115","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jchromb.2014.05.042","article-title":"Determination of irinotecan and its metabolite SN-38 in rabbit plasma and tumors using a validated method of tandem mass spectrometry coupled with liquid chromatography","volume":"962","author":"Park","year":"2014","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003902?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023223003902?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T23:12:10Z","timestamp":1761606730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023223003902"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":23,"alternative-id":["S1570023223003902"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123980","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an UPLC-MS\/MS method for the determination of irinotecan (CPT-11), SN-38 and SN-38 glucuronide in human plasma and peritoneal tumor tissue from patients with peritoneal carcinomatosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2023.123980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123980"}}